Skip to content
Wednesday, March 29, 2023
Latest:
  • 6sense Unveils Revolutionary AI-Powered Revenue Creation Technology
  • What it Really Means to be Data-Driven as B2B Social Media Manager
  • Most Automation Transformations Fall Short, Despite Opportunity to Reduce Costs by as Much as 30%
  • ScaleWith Announces the Launch of BuyWith
  • 6sense Has Fifth Consecutive Year of Sustained Growth Including Industry-Leading Revenue and Customer Success
The ABM

The ABM

AccountBaseManagement

Connect With Us

Visit Us On TwitterVisit Us On FacebookVisit Us On Linkedin
Clickadu

  • NEWS
    • Featured News
    • Trending News
  • EVENTS
    • Upcoming Conferences
    • Past Conferences
    • Live Webinars
    • On-Demand Webinars
  • Companies
  • RESOURCES
    • Articles
    • Videos
    • Whitepapers
    • Infographics
  • Forums
    • General Discussion
  • Blogs
theabm
Featured News 

Portfolio Highlights: Clinical and Financial Updates of ABM, F5, AceLink, HAYA, Regenacy, and Arthrosi

September 29, 2022 hitesh nikam Account based marketing, Account-Based Sales, B2B, B2B Marketing, theabm

As the investment division of Viva Biotech, Viva BioInnovator is committed to being a collaborative platform for Innovative Biotech companies from around the world. Over the past 2 months, our portfolio companies progressed greatly.

ABM Therapeutics Announces First Patient Dosed in Phase I Clinical Trial of ABM-1310 in China

On September 16, 2022, ABM Therapeutics, a clinical-stage biopharmaceutical company that is invested and incubated by Viva BioInnovator, announced that the first patient has been successfully dosed with ABM-1310 in a multi-center phase I clinical trial in China.

ABM-1310, ABM Therapeutic’s proprietary clinical candidate developed as a next-generation BRAF inhibitor, is a highly selective, highly water-soluble, orally administrated, and brain-penetrant small molecule BRAF inhibitor. ABM-1310 phase I trial, conducted in China, is a multi-center, open-label study to investigate the safety, tolerability, pharmacokinetics, and preliminary anti-tumor activity of ABM-1310 in Chinese patients with BRAF V600X mutated advanced solid tumors.

F5 Therapeutics awarded First Servier FAST Discovery Award

F5 Therapeutics, which invested and incubated by Viva BioInnovator, was recently awarded the first Servier FAST Discovery Award. Winning this award means F5 stood out from 23 applications, indicating the industry’s recognition of F5’s innovative treatment methods in the field of biomedicine. “Servier FAST Discovery Award” is co-sponsored by Servier and the California Life Sciences Association (CLSA) to support early-stage life science companies using innovative approaches in areas designated by the group: oncology, auto-immune diseases, genetically driven neurodegenerative, and movement disorders.

F5 is transforming targeted protein degradation to advance drug discovery by utilizing the cell’s normal protein regulation systems to remove disease-causing proteins that cannot be targeted by traditional approaches. The NExMods™ Platform (NEosubstrate Expression Modulators) represents a novel approach to “molecular glues” capable of delivering effective medicines to patients across diverse therapeutic areas: oncology, immuno-oncology, fibrosis, inflammation, and neurodegeneration.

AceLink Therapeutics Receives Orphan Drug Designation for its Novel GCS inhibitor AL01211 for the Treatment of Fabry Disease

AceLink Therapeutics, Inc. (AceLink), invested and incubated by Viva BioInnovator, is an innovative biopharmaceutical company developing transformative therapies for genetic diseases. On September 7, 2022, they announced that they received Orphan Drug Designation (ODD) from the U.S. Food and Drug Administration (FDA) for AL01211 as a treatment for Fabry Disease.

AL01211 was selected based on its unique properties to effectively treat peripheral organs that Fabry disease affects by reducing the risk of off-target effects by preventing the crossing of the blood-brain barrier.

HAYA Therapeutics won the “TOP 100 Swiss Startup Award 2022” and was successfully selected for the “Soonicorn Club 2022”

On Sept. 7th, 2022, the “Top 100 Swiss Startup Award 2022,” sponsored by Venturelab, was announced. HAYA Therapeutics, invested and incubated by Viva BioInnovator, was named TOP100 Swiss Startups’ 8th Best Startup and came first in the Cardiovascular & Drug Discovery sectors. In addition, HAYA Therapeutics was recently included in the”SoonicornClub 2022″, which names the top Swiss technology startups. The awards given demonstrate the industry’s recognition of their potential in the field of biomedicine.

Regenacy Pharmaceuticals Announces Completion of Enrollment for their Phase 2 Study in Diabetic Peripheral Neuropathy and $9.3 Million in Series B Financing

Regenacy Pharmaceuticals Inc, invested and incubated by Viva BioInnovator, is a clinical-stage, biopharmaceutical company developing breakthrough treatments for diabetes and other peripheral neuropathies. On August 24, 2022, they announced completion of enrollment for the company’s phase 2 study of ricolinostat, an oral selective deacetylase 6 (HDAC6) inhibitor for painful diabetic peripheral neuropathy (DPN). The company also announced the closing of a $9.3 million Series B financing led by Cobro Ventures.

Arthrosi Completes AR882 Renal Impairment Study and its Phase 2b Study Enrollment

Arthrosi Therapeutics, Inc., which invested and incubated by Viva BioInnovator, is a clinical-stage biotechnology company focused on the treatment and management of gout. On August 9, 2022, they announced the completion of their renal impairment study that utilizes the lead compound, AR882. AR882 is a potent and selective uricosuric agent which has shown effectiveness in lowering serum urate in patients with normal renal function and in patients with mild to severe renal impairment.

On Aug. 23, 2022, Arthrosi announced the completion of enrollment for its global Phase 2b clinical study of AR882 for the treatment of chronic gout. The study, which exceeded the initial target enrollment of 120 patients, is designed to evaluate the safety and efficacy of AR882 in chronic gout patients who meet ACR/EULAR gout classification.

 

  • ← AdDaptive Intelligence Launches New Website and Logo
  • TechTarget Launches Prospect-Level Purchase Intent Data for Healthcare in Latest Release of its Priority Engine Platform →

You May Also Like

theabm

Aurora Mobile’s Subsidiary SendCloud Partners with Moka to Help HR SaaAurora Mobile Limited (NASDAQ: JG) (“Aurora Mobile” or the “Company”), a leading provider of customer engagement and marketing technology services in China, today announced that its subsidiary Wuhan SendCloud Technology Co., Ltd. (“SendCloud”) has entered into a strategic partnership with Moka, a leading HR SaaS provider in China. Leveraging its cutting-edge email technology, SendCloud will provide Moka with high-efficiency email services, helping it optimize customer reach. This partnership is another validation of the industry-wide acclaim and trust that SendCloud commands for the high-quality services it offers to SaaS companies. Since its establishment in 2015, Moka has been growing very fast and is committed to empowering enterprises with data-driven intelligent HR SaaS solutions leveraging its strong technology and services. Moka has received investments from a number of renowned institutional investors such as GGV Capital, Jinsha River Venture, Hillhouse Capital, Xianghe Capital, Blue Lake Capital, and Tiger Global Fund. In November 2021, Moka raised US$100 million in Series C financing. About Aurora Mobile Limited Founded in 2011, Aurora Mobile (NASDAQ: JG) is a leading provider of customer engagement and marketing technology services in China. Since its inception, Aurora has focused on providing stable and efficient messaging services to enterprises and has grown to be a leading mobile messaging service provider with its first-mover advantage. With the increasing demand for customer reach and marketing growth, Aurora has developed forward-looking solutions such as Cloud Messaging and Cloud Marketing to help enterprises achieve omnichannel customer reach and interaction, as well as artificial intelligence and big data-driven marketing technology solutions to help enterprises’ digital transformation.S Provider Optimize Customer Reach

August 26, 2022September 14, 2022 hitesh nikam
Account-Based Marketing Strategy In Place

Foundry Study Says 96% of B2B Marketers Have A Documented Account-Based Marketing Strategy In Place

November 2, 2022November 2, 2022 hitesh nikam
theabm

MRP Prelytix Media Alert: Research VP to Share Insights on the Heightened Complexities and Opportunities of Enterprise ABM

June 22, 2021August 25, 2022 Admin

On-Demand Webinars

theabm
On-Demand Webinars 

ABM – Account-Based Marketing Leaders Forum APAC 2022

hitesh nikam

In 2020, we launched APAC’s first Account Based Marketing – ABM focused Forum. With over 450 paid online registrants, it

theabm
On-Demand Webinars 

The Gartner Magic Quadrant for ABM Platforms

hitesh nikam
theabm
On-Demand Webinars 

The Secret to Building Better ABM Experiences

hitesh nikam
theabm
On-Demand Webinars 

Fundamentals of ABM: An ITSMA

Admin
theabm
On-Demand Webinars 

B2B Earthquakes: Building Strategy and Plans to Bend, Not Break

Admin
theabm
On-Demand Webinars 

ABM Leaders Virtual Forum APAC: Building the Team to Enable Strong ABM Strategy, Plan, and Execution

Admin

Videos

Featured Video Play Icon
Videos 

What it Really Means to be Data-Driven as B2B Social Media Manager

March 14, 2023 hitesh nikam

The strongest strategies are those that are data-driven. But what does that look like in the B2B social media industry,

Featured Video Play Icon
Videos 

Breaking Silos and Unlocking the Potential of Social for Business Growth

February 7, 2023February 21, 2023 hitesh nikam
Featured Video Play Icon
Videos 

Why ABM is a Must During a Down Economy?

November 7, 2022January 24, 2023 hitesh nikam
theabm
Videos 

Why is ABM so integral to a B2B company’s success?

January 12, 2022August 24, 2022 hitesh nikam

Company

theabm
Companies 

The Mezzanine Group

December 8, 2020August 24, 2022 Admin

Mezzanine B2B Growth Agents works with senior leaders in manufacturing, technology, and business services companies to generate leads, accelerate sales

theabm
Companies 

WAM We Are Marketing

December 8, 2020August 24, 2022 Admin
theabm
Companies 

WUG Marketing

December 8, 2020August 24, 2022 Admin
theabm
Companies 

b2b partnerships

December 8, 2020August 24, 2022 Admin
theabm
Companies 

B2B News Network

December 8, 2020August 24, 2022 Admin
abm

Click To Unsubscribe

Useful Link

  • PRIVACY POLICY
  • COOKIES
  • TERMS OF SERVICE

Email Subscription

Loading

Connect With Us

Visit Us On TwitterVisit Us On FacebookVisit Us On Linkedin

Click To Data Request

Data Request
Copyright © 2022 The ABM.All rights reserved.
Please wait...

Subscribe to our newsletter

Want to be notified when our article is published? Enter your email address and name below to be the first to know.
SIGN UP FOR NEWSLETTER NOW